Table 1 Reasons for the use of products supported by evidence-based evaluation of safety and efficacy
From: Allergen immunotherapy on the way to product-based evaluation—a WAO statement
The efficacy of the product is known and sufficient (it may fulfill the WAO criteria of 20 % over placebo for rhinitis [3] and appropriate criteria for asthma and other organ manifestations) |
The safety of the product is known and favorable; risks for the patient can be evaluated |
If efficacy and safety in children are known, the usefulness of the product in children can be evaluated |
If information on long-term effects is available for the product, theinformation can be used for calculations of the socio-economic impact |
If the tolerability or the efficacy in asthma patients is known, the usefulness and risks of the product for therapy in asthmatic populations can be estimated |